Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment (EAGLES)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Unresectable, advanced or metastatic histologically confirmed leiomyosarcoma
Progression during or after first-line doxorubicin-based chemotherapy (relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doxorubicin-based regimen could be considered as first-line therapy.)
ECOG PS 0-2
At least one measurable lesion according to RECIST v1.1
Adequate organ function
Life expectancy >= 3 months
Negative serum or urine pregnancy test at screening for women of childbearing potential
Prior treatment history of anti-PD-1/PD-L1 or anti-CTLA4 treatment
Receipt of 2 or more prior systemic treatments for advanced leiomyosarcoma
Active or untreated brain metastases or spinal cord compression
Prior treatment with gemcitabine
History of major surgery within 4 weeks prior to enrollment
Chemotherapy or radiotherapy within 3 weeks prior to the study drug commencement
Previous malignant disease other than leiomyosarcoma within the last 5 years with the exception of basal or squamous cell carcinoma of skin or carcinoma in situ (bladder, cervical, colorectal, breast)
Pregnant or lactating women
HIV, HBV, or HCV infection
Severe hypersensitivity or anaphylaxis to monoclonal antibody, or uncontrolled bronchial asthma
Current use of immunosuppressive agent (exclusion : less than prednisone 10 mg/day or equivalent)
Active autoimmune disease
Clinically significant cardiovascular disease
Clinically significant interstitial pneumonitis or pulmonary fibrosis
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines